Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist, Non-Viral Vector Analytical

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Oct 8, 2021

View more

Job Details

Why Join Intellia? 

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. 

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done. 

We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.   

How you will Achieve More with Intellia:

As a Scientist in the Non-Viral Vector Biology group you will help advance Intellia’s gene editing platform and pipeline. The candidate will work collaboratively with our research and Tech Ops teams to identify, develop, and implement appropriate analytical methods for characterizing synthetically produced DNA payloads. The successful candidate will be a subject matter expert in analytical methods for nucleic acid. Key responsibilities include:

  • Development of methods for analyzing materials prior to testing in cell and animal models

  • Design, plan, and execute analytical experiments working both independently and as part of a multidisciplinary team of researchers, including partnering closely with Tech Ops

  • Introduce new analytical technologies and implement common reagents and controls

  • Tech transfer methods to the Analytical Development team

  • Author and review protocols

  • Interpret and communicate data as part of multi-disciplinary teams

  • Maintain a detailed electronic laboratory notebook

About You:

We are seeking an innovative scientist with expertise analyzing and qualifying nucleic acid drug products. The ideal candidate thrives on working collaboratively with multidisciplinary teams, displays outstanding communication skills, and is passionate about pioneering new gene-editing technologies to treat human disease. Other important qualities include:

  • Ph.D. in Chemistry, Chemical Engineering, Biomolecular Engineering, Biochemistry, or a related field

  • Hands-on experience optimizing and executing nucleic acid testing and characterization techniques (e.g. HPLC, SDS-PAGE, CD, DLS, SEC-MALS, AF4-MALS, ELISA, NGS, cell-based potency assays)

  • General knowledge of non-viral delivery methods, LNP formulation, and standard molecular biology laboratory techniques

  • Excellent bench skills with attention to detail and high standards for data integrity and quality

  • Highly organized

  • Strong communication skills with the proven ability to work collaboratively

  • Passion for applying new techniques and technologies

Meet your Future Team:

The Platform Innovation team is a collaborative, energetic, and passionate group of individuals whose mission is to advance and differentiate Intellia’s platform to enable curative therapies. You will join a team with vector design and production expertise, and work closely with leaders in the field of CRISPR/Cas9 gene editing. The candidate will have many opportunities to broaden his or her experience with multiple cutting-edge gene therapy technologies that advance Intellia’s pipeline. 

The team is currently working mostly onsite to execute workflows in a wet-lab environment. Therefore, the candidate must be local to Cambridge MA, or open to relocating. While some of the day-to-day operations may be home-office based, maintaining a strong relationship with your teammates is critical for conveying your scientific expertise while fostering an environment for growth of young scientists interested in a career in the biotech industry. If you join us, you can expect to be part of a hardworking and collaborative environment. We look forward to fostering your skills, learning from your experiences, and building a larger team to make a difference in patients’ lives.

#LI-DG1

Covid-19 Vaccination Policy: Effective Monday, January 3, 2022, all Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert